Market Performance - On December 1, the medical device sector rose by 0.02% compared to the previous trading day, with Haooubo leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Top Gainers in Medical Device Sector - Haooubo (688656) closed at 211.50, with a gain of 5.80% and a trading volume of 13,300 shares, amounting to a transaction value of 278 million yuan [1] - Kangzhong Medical (688607) closed at 32.93, up 5.07%, with a trading volume of 59,200 shares, totaling 197 million yuan [1] - Mailande (688273) closed at 37.47, gaining 4.90%, with a trading volume of 18,400 shares, amounting to 67.98 million yuan [1] Top Losers in Medical Device Sector - Shuoshi Biology (688389) closed at 67.16, down 4.67%, with a trading volume of 22,800 shares, totaling 155 million yuan [2] - Yirui Technology (688301) closed at 100.84, down 2.87%, with a trading volume of 21,800 shares, totaling 221 million yuan [2] - Kangwei Century (688426) closed at 27.09, down 2.76%, with a trading volume of 17,400 shares, totaling 48.29 million yuan [2] Capital Flow Analysis - On the same day, the medical device sector experienced a net outflow of 137 million yuan from institutional investors, while retail investors saw a net outflow of 89.79 million yuan [2] - However, there was a net inflow of 227 million yuan from speculative funds [2] Individual Stock Capital Flow - Zhend Medical (603301) had a net inflow of 35.80 million yuan from institutional investors, while it experienced a net outflow of 24.97 million yuan from retail investors [3] - Zhenghai Biology (300653) saw a net inflow of 30.45 million yuan from institutional investors, but a net outflow of 31.84 million yuan from retail investors [3] - Yirui Technology (688301) had a net inflow of 16.88 million yuan from speculative funds, while retail investors experienced a net outflow of 38.19 million yuan [3]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [6][54]. Core Viewpoints - The IVD market is expected to benefit from a recent policy initiative aimed at enhancing the adaptability of supply and demand for consumer goods, with a focus on high-end medical devices and efficient IVD equipment [5][53]. - The domestic biochemical diagnostics sector has largely overcome reliance on foreign technologies, indicating a completed process of localization [6][54]. - The report emphasizes the shift towards home health management, moving from a treatment-centered to a prevention-centered approach, which is expected to create a trillion-yuan integrated market [5][53]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.67%, with the IVD sector increasing by 2.63% during the week [2][12]. - The IVD sector's current PE ratio is 39.84X, with a PB ratio of 1.85X, reflecting a slight increase from the previous week [4][33]. Company Performance - Notable performers in the medical services sector include Haobio (+14.3%), Shuoshi Biological (+13.6%), and Innotech (+13.3%) [3][29]. - Underperformers include *ST Dongyang (-7.2%) and New Industry (-5.7%) [3][29]. Investment Recommendations - The report suggests focusing on companies in the IVD sector that cater to home consumption scenarios, such as Shengxiang Biological and Sannuo Biological [5][54]. - It highlights the importance of monitoring the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics like PCR [6][54].

Core Viewpoint - The medical device sector is experiencing slight fluctuations, with the medical device ETF reaching a historical high of 3.22 billion yuan, despite a minor decline of 0.11% [1] Industry Overview - The global IVD (in vitro diagnostics) market is maintaining steady growth, while the domestic market faces some pressure due to DRG/DIP policies. However, the demand for medical testing remains robust due to aging demographics [1] - The domestic biochemical diagnostics sector has largely overcome foreign dependencies, with the localization process nearly complete [1] Company Developments - The "Qiyuan Inspection Model," the first vertical large model focused on clinical testing in China, was officially launched at the Southern Inspection Medicine Academic Conference. This model was developed collaboratively by Mindray Medical and Southern Medical University Shenzhen Hospital, with support from multiple departments in Shenzhen [1] - The "Qiyuan" model differentiates itself from general large models by systematically building the reasoning and thinking capabilities of medical experts through a four-step process: professional learning, clinical training, thinking simulation, and continuous evolution [1] Market Performance - As of 14:24 on November 26, the medical device ETF (562600) showed a slight decline of 0.11%, with leading stocks including Haorunbo, Weili Medical, Lexin Medical, Dian Diagnostics, and Shuoshi Biology showing strong upward trends [1]

Group 1 - The A-share market is experiencing an upward trend, with the medical device sector remaining active, as evidenced by the medical device ETF (562600) increasing by 0.8% and reaching a historical high of 322 million yuan [1] - Shanghai has introduced new policies to promote innovation and acceleration in the medical device industry, including prioritizing innovative review procedures for second-class innovative medical devices with significant clinical value and reducing the average registration cycle to under 6 months [1] - CITIC Securities believes that long-term investment opportunities in the medical device sector stem from innovation, international expansion, and mergers and acquisitions, with the sector's innovation and international capabilities being recognized and valuations being reassessed [1] Group 2 - The medical device industry is rapidly developing, and investors can leverage the medical device ETF (562600) to capture growth opportunities, as it tracks the CSI All Index Medical Device Index, which includes 100 representative companies with a high industry concentration of 89.3% [2] - For off-market users, there are options to invest in the Huaxia CSI All Index Medical Device ETF Initiated Link A (021250) and Link C (021251) for convenient exposure [2]

Group 1 - The stock price of Haobo Bio has increased by 1.08% to 184.68 CNY per share, with a trading volume of 135 million CNY and a turnover rate of 1.15%, resulting in a total market capitalization of 11.723 billion CNY [1] - Haobo Bio's stock has risen for three consecutive days, with a cumulative increase of 6.66% during this period [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with 89.46% of its revenue coming from reagent sales [1] Group 2 - According to data, one fund under China Merchants Fund holds Haobo Bio as its ninth largest position, with a net value proportion of 4.31% [2] - The fund, China Merchants Growth Pioneer Stock A, reduced its holdings by 603 shares in the third quarter, now holding 10,700 shares [2] - The fund has achieved a year-to-date return of 30.67% and a one-year return of 23.52%, ranking 1082 out of 4206 and 1713 out of 3983 respectively [2]

Group 1 - The core point of the article highlights the recent performance of Jiangsu Haobo Bio-Pharmaceutical Co., Ltd., which saw a 5.1% increase in stock price, reaching 183.80 yuan per share, with a trading volume of 146 million yuan and a turnover rate of 1.30%, resulting in a total market capitalization of 11.668 billion yuan [1] - The company, established on June 8, 2009, and listed on January 13, 2021, specializes in the research, production, and sales of in vitro diagnostic reagents, with its main revenue sources being reagent sales (89.46%), other sales (5.86%), instrument sales (3.84%), and rental sales (0.85%) [1] Group 2 - From the perspective of fund holdings, only one fund under Industrial Bank has a significant position in Haobo Bio, specifically the Industrial Medical Care A fund, which held 96,900 shares in the third quarter, accounting for 3.8% of the fund's net value, making it the tenth largest holding [2] - The Industrial Medical Care A fund, established on March 8, 2021, has a current size of 261 million yuan, with a year-to-date return of 19.11%, ranking 3578 out of 8209 in its category, and a one-year return of 11.73%, ranking 4678 out of 8129 [2] - The fund manager, Chen Xu, has been in position for 4 years and 263 days, with the total asset size of the fund being 404 million yuan, and the best and worst returns during his tenure being -22.64% and -24.44%, respectively [2]

证券代码：688656 证券简称：浩欧博 公告编号：2025-065 江苏浩欧博生物医药股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 1、出席会议的股东和代理人人数 | 20 | | --- | --- | | 普通股股东人数 | 20 | | 2、出席会议的股东所持有的表决权数量 | 43,207,515 | | 普通股股东所持有表决权数量 | 43,207,515 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 68.9352 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（% | 68.9352 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长 JOHN LI 先生主持，会议以现场 （一） 股东大会召开的时间：2025 年 11 月 14 日 （二） 股东大会召开的地点：公司会议室 本次会议是否有被否决议案：无 一、 会议召开和出席情 ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于江苏浩欧博生物医药股份有限公司 2025 年第四次临时股东大会的法律意见书 致：江苏浩欧博生物医药股份有限公司 江苏浩欧博生物医药股份有限公司（以下简称"公司"）2025 年第四次临时 股东大会定于 2025 年 11 月 14 日召开，国浩律师（上海）事务所（以下简称"本 所"）接受公司的委托，指派倪俊骥律师、李嘉言律师（以下简称"本所律师"） 对本次股东大会进行见证，并依据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管 理委员会发布的《上市公司股东会规则》及其他现行有效的法律、法规及规范性 文件规定及《江苏浩欧博生物医药股份有限公司章程》（以下简称"《公司章程》"） 出具本法律意见书。 本所律师按照中华人民共和国（以下简称"中国"，仅为本法律意见书之目的， 不包括香港特别行政区、澳门特别行政区和台湾地区）现行法律、法规的规定， 列席了本次股东大会，审查了公司提供的有关本次股东大会各项议程及相关文件， 对本次股东大会的召集、召开程序是否合法及是否符合《公司章程》规定、出席 ...

中国国际金融股份有限公司 关于 双润正安信息咨询（北京）有限公司 要约收购江苏浩欧博生物医药股份有限公司 之 2025 年第三季度持续督导意见 中国国际金融股份有限公司（以下简称"中金公司"、"本财务顾问"）接受收购人双 润正安信息咨询（北京）有限公司（以下简称"收购人"、"双润正安"）委托，担任其要 约收购江苏浩欧博生物医药股份有限公司（以下简称"上市公司"、"浩欧博"）之财务顾 问，持续督导期为要约收购报告书公告日起至要约收购完成后的 12 个月止，即 2024 年 12 月 20 日至 2026 年 2 月 14 日。根据相关法律法规规定，本财务顾问出具 2025 年 第三季度（即 2025 年 7 月 1 日至 2025 年 9 月 30 日，以下简称"本持续督导期"）的持 续督导意见。 一、交易资产的交付或过户情况 2024 年 10 月 30 日，浩欧博控股股东海瑞祥天生物科技（集团）有限公司（以下 简称"海瑞祥天"）及其一致行动人苏州外润投资管理合伙企业（有限合伙）（以下简 称"苏州外润"）、公司时任实际控制人 JOHN LI、WEIJUN LI、陈涛与双润正安及其 一致行动人北京辉煌润康医药发 ...

Market Overview - The medical device sector experienced a slight decline of 0.13% on November 11, with Danaher Biomedical leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Top Performers - Anxu Bio (688075) saw a closing price of 42.54, with an increase of 4.39% and a trading volume of 23,700 [1] - Nanwei Medical (688029) closed at 86.17, up 3.89% with a trading volume of 31,700 [1] - Yirui Technology (688301) closed at 109.90, increasing by 2.65% with a trading volume of 22,000 [1] Underperformers - Danaher Biomedical (920009) closed at 77.69, down 4.91% with a trading volume of 16,300 [2] - Ruimait (301367) closed at 86.41, down 4.32% with a trading volume of 18,600 [2] - Tianchen Medical (688013) closed at 52.68, down 3.59% with a trading volume of 26,900 [2] Capital Flow - The medical device sector saw a net outflow of 642 million yuan from institutional investors, while retail investors contributed a net inflow of 463 million yuan [2][3] - The top net inflows from retail investors were observed in Nanwei Medical (688029) with 46.22 million yuan, and Tianchen Medical (688013) with 24.78 million yuan [3]